Analysis Pharma Mar SA (PHMMF)
6/3/2024
Analysis of Pharma Mar SA (PHMMF)
Pharma Mar SA (PHMMF) has shown a consistent uptrend in the stock price over the past few days. The Relative Strength Index (RSI) is indicating overbought conditions at 72.63, suggesting a possible reversal or correction in the near future.The Moving Average Convergence Divergence (MACD) indicator is positive, with the MACD line above the signal line and a positive MACD histogram. This indicates bullish momentum in the stock.
The Moving Average (MA) indicator is also showing an upward trend, with the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) all trending higher.
Overall, Pharma Mar SA seems to be in a strong bullish trend, but traders should be cautious of a possible correction due to the overbought RSI levels. It would be advisable to monitor the stock closely for any signs of a reversal in the coming days.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, showing a sales growth of 3% compared to the previous year's same quarter. The number of analysts providing estimates remains at 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates increases to 38.
4. Looking ahead to the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, indicating a significant sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates remains at 38.
These estimates suggest a moderate but steady growth trend in both quarterly and annual sales for the company over the specified periods.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest that the company has been experiencing strong growth in the past, and analysts expect this growth to continue at a slightly lower but still healthy rate in the coming years.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
- Currency: USD
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security, with a median forecast above the current price. However, there is a wide range of predictions, from a low of $164 to a high of $275, indicating some uncertainty in the market.
Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided yet. The previous results from February 27, 2025, were related to the transfer agent. The results from January 31, 2025, were released after hours. The results from October 31, 2024, were not provided at a specific time. The results from August 1, 2024, showed an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive profit margin and healthy return on assets and equity. The balance sheet shows a current ratio slightly above 1, indicating good liquidity, but a high total debt to equity ratio. The income statement highlights significant revenue and EBITDA, with a positive diluted EPS and net income.
Stock statistics reveal details about the company's shares, including short interest, float shares, and trading volumes. The company has a significant market capitalization and enterprise value, with relatively high valuation metrics such as P/E ratios and price to book.
The stock price summary includes information on the stock's performance, such as beta, moving averages, and the 52-week high and low prices. The company also pays dividends, with details on dividend dates, rates, and yields, as well as historical stock splits.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales have been increasing steadily over the past four years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite fluctuations in other financial metrics, the revenue trend shows consistent growth.
3. The company's ability to generate revenue has been strong, indicating a healthy demand for its products or services.
4. Investors and analysts may view this revenue growth positively as it reflects the company's market position and potential for future profitability.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been fluctuating, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. Financing activities show significant fluctuations, especially in common stock repurchases and long-term debt issuuance.
5. Investing activities also vary, with notable amounts spent on the sale and purchase of investments.
6. The end cash position has been fluctuating, but generally, the company has maintained a healthy cash reserve.
7. Stock-based compensation has been a significant factor in the company's financial activities.
8. The company has been paying dividends consistently, with varying amounts each year.
9. The company has engaged in acquisitions and divestitures, impacting the investing cash flow.
10. Overall, the company's cash flow statement reflects a mix of stability and variability in its financial activities over the years.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This is higher than the EPS of $1.35 from the same quarter last year.
3. For the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.10, with a low estimate of $5.95 and a high estimate of $6.41. This reflects growth from the EPS of $5.67 in the previous fiscal year.
4. Looking ahead to the next fiscal year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This indicates a potential increase from the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates suggest a positive outlook for the company's earnings per share, with expected growth in both the short term and the long term.
MACD of PHMMF
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
